

The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**MONDAY
MAY 04TH**

8:00 – 8:30		
Registration and Joint Breakfast in Foyer, attach Posters		
8:30 – 8:55		
Opening of the Conference – <i>Andreas Köpke, bioExpert</i>		
8:55		
Development of the Life ScienceHub Mainz – <i>Tim Roos, biomindz</i>		
9:00 – 9:30		
Cellular Senescence and Aging in Neurodegenerative Diseases: Opportunities for Drug Discovery? <i>Chair: Roger Sher, Stony Brook University, USA</i>		
PANEL 09:30 – 10:30		
Senescence in Neurodegeneration	HMGB1 mediates senescence and cognitive dysfunction in tauopathies	Rakez Kaye UTMB, USA
	Aging, inflammation, and neurodegeneration: Unraveling the senescent brain in Parkinson's disease	Markus Riesland Stony Brook University, USA
Animal Models of PD	<i>In vivo</i> models for Parkinson's disease translation: Connecting mechanism, efficacy, and biomarkers	Ayşe Ulusoy DZNE Bonn, Germany
Panel Q&A of Session Speakers <i>Chair: Roger Sher, Stony Brook University, USA</i>		
10:30 – 11:30		
Coffee Break, Exhibition & Poster viewing		
PANEL 11:30 – 12:30		
New AD Mode of Action	Identification of a novel A β (pGlu3-x) targeting pathway in Alzheimer's disease	Sarah Schrepel University of Leipzig, Germany
New AD Mode of Action	Finding the right target for A β immunotherapy – PTM-targeting antibodies differentially mediate inflammation and phagocytosis	Stefan Schilling IZI Fraunhofer Inst., Germany
	Lysosome targeting in Parkinson's disease: From pathophysiology to therapy	Friederike Zunke Friedrich-Alexander-University, Germany
Panel Q&A of Session Speakers <i>Chair: Roger Sher, Stony Brook University, USA</i>		
12:30		
Lunch		

The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**MONDAY
MAY 04TH**

13:30		
TREM2 agonism – where do we stand and what is needed for therapy? <i>Chair: Christian Haass, DZNE, LMU, Germany</i>		
PANEL 14:00 – 15:00		
Neuroinflammation	Brain-Shuttle mediated TREM2 PET for highly specific assessment of activated myeloid cells	Matthias Brendel LMU, Germany
	TREM2 activation: Harnessing the brain's immune system to treat neurodegeneration	Agnes Cheong Sanofi, UK
	Transport vehicle engineering improves activity of TREM2 antibodies	Lihong Zhan Denali, USA
Panel Q&A of Session Speakers <i>Chair: Christian Haass, DZNE, LMU, Germany</i>		
15:00 – 16:00		
Coffee Break, Exhibition & Poster Session (Presenters will be at their posters.) Time for One on One Meetings		
PANEL 16:00 – 17:00		
Neuroinflammation	Inhibition of prolyl endopeptidase to reduce neuroinflammation	Franziska Richter Assencio Center for Systems Neuroscience Hannover, Germany
Service Company Presentation	De-risking drug development in neurodegenerative and age-related diseases	Stefan Ebner-Behnke Scantox, Austria
TDP-43 Aggregates and Disease	Misfolded TDP-43 transmits intercellularly via large seeding particles, and is toxic intracellularly via small oligomers	Neil Cashman UBC, Canada
Panel Q&A of Session Speakers <i>Chair: Christian Haass, DZNE, LMU, Germany</i>		
17:00		
Reception in the foyer with local wine and beer specialties		
17:30		
From Data to Dialogue: Toasting to Better Science Conversations <i>Laura Lindenfeld, Alan Alda Center for Communicating Science, USA</i>		
18:30 – 22:00		
Dinner We will have a seated BBQ dinner, accompanied by fitting local wines! Depending on the weather, we will be on the hotel terrace, or in an adjacent room.		
END OF THE FIRST DAY		

The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 05TH**

8:00		
Joint Breakfast, Exhibition & Poster Viewing		
PANEL 9:00 – 10:00		
New MoA	Amisulpride derivative as novel drug in tau-associated neurodegenerative diseases	Josephine Labus MHH, Germany
Clearing toxic protein aggregates	Detangling toxic aggregates	Dieter Willbod Priavoid, Germany
Therapeutic Improvements	Delivering α -synuclein antibodies into the brain via the BrainTransporter™ technology	Fredrik Eriksson Bioarctic, Sweden
<p>Panel Q&A of Session Speakers <i>Chair: Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany</i></p>		
10:00 – 11:00		
<p>Coffee Break, Exhibition & Poster Session (Presenters will be at their posters.) Time for One on One Meetings</p>		
11:00 – 11:30		
<p>On the trail of protein aggregates: using RT-QuIC to detect α-synuclein aggregates in salivary gland biopsies <i>Chair: Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany</i></p>		
PANEL 11:30 – 12:30		
Blood diagnosis	Neuro-IP as method for improvement of Alzheimer's disease diagnostic by blood tests	Ingolf Lachmann Roboscreen GmbH, Germany
Nasal sampling for diagnosis	Beyond CSF and Blood: Nasal fluid as a window into brain biology	Sabine Mertzig Noselab, Germany
Seed quantification	From misfolding to medicine: SeNostic's Seed Cyclor enables diagnosis and drug discovery for proteopathies	Joachim Glaubitz SeNostic, Germany
<p>Panel Q&A of Session Speakers <i>Chair: Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany</i></p>		
12:30		
Lunch		

The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE
DISEASE
DRUG
DISCOVERY

**TUESDAY
MAY 05TH**

13:30

Disease modifying therapies in Alzheimer's disease based on individual neurobiological staging
Chair: *Oliver Peters, Charité, Germany*

PANEL 14:00 – 15:00

New Therapeutic Option

TRB-001, a novel α -synuclein-based vaccine for the treatment and prevention of Parkinson's disease

Achim Schneeberger
Tridem Bioscience,
Austria

Clinical Trials in AD

BMS' disease modifying and symptomatic therapies currently in clinical development for Alzheimer's disease

Daniel Ridley
BMS, UK

Marketing approval and reimbursement

From EMA to G-BA: Implementing anti-amyloid therapy in Germany

Lutz Frölich
U. Heidelberg, Germany

Panel Q&A of Session Speakers

Chair: *Oliver Peters, Charité, Germany*

15:00

Coffee Break & Final Poster Session

15:30

Panel Diskussion:

- Is the GBA decision justified and final – and what does that mean for future AD therapy developments?
- How can the current immunotherapy be improved in terms of efficacy and safety?
- How accurate are current and developing diagnostics for neurodegenerative diseases and what are the implications for patients and therapies?
- Should new therapies focus on neuroinflammation and improvement of synaptic health?

Panel Participants: *Oliver Peters, Lutz Frölich, Neil Cashman, Wiebke Jürgens-Wemheuer, Christian Haass*

Moderator: *Andreas Köpke*

16:15

Potser price, Summary and Wrap-up of the conference

16:30

END OF THE CONFERENCE AND DEPARTURE